| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b8603ee14f13e9c3d3f6d5858bf4f3bf |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57563
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 |
| filingDate |
2008-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aeb7d85a22e9e7b97d9d95376793ac72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e006f7a62d88c52b00381050eba7c46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1308ffc8c916da13fd371dfcd3d61853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_779b96dc5ed55256a273e311a040648f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85ff639913f0e9a9ac25865b97d3522f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ead46aa266928b6511fd84457a39e3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7321d0179585d72efc38c56b4f08a420 |
| publicationDate |
2009-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-200922615-A |
| titleOfInvention |
Insulinotropic peptide derivative wherein its N-terminal amino acid is modified |
| abstract |
The present invention relates to an insulinotropic peptide derivative having an improved insulinotropic activity and blood stability, and a pharmaceutical composition for the treatment of diabetes, comprising the insulinotropic peptide derivatives. In particular, the present invention is characterized in N-terminal amino acid-modified insulinotropic peptide. The insulinotropic peptide derivatives according to the present invention exhibit therapeutic effects, which are not observed in native and other insulinotropic peptide analogs. Therefore, the insulinotropic peptide derivatives and the pharmaceutical composition comprising the same according to the present invention can be effectively provided for the treatment of the diseases. |
| priorityDate |
2007-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |